Lutetium-177 PSMA therapy (sold as Pluvicto) delivers targeted radiation directly inside prostate cancer cells. A small molecule binds to PSMA — a protein found on prostate cancer cells — and the attached Lu-177 atom emits short-range beta radiation that destroys the cancer from within. German centres in Heidelberg, Munich, and Bad Berka deliver 4-6 cycles every 6-8 weeks for men with advanced, hormone-resistant prostate cancer.
Reply in 4 hours · Plan and quote in 2 days · 100% confidential
Lu‑177 PSMA therapy—often called Lutetium‑177 PSMA‑617 or by its brand name Pluvicto—is transforming the way we treat advanced prostate cancer. Unlike conventional therapies that target the whole body, this innovative treatment delivers radiation directly to cancer cells, minimizing harm to healthy tissues. It’s a shining example of precision medicine—where science meets compassion.
Germany stands at the forefront of this medical breakthrough, having played a key role in developing and refining Lu‑177 PSMA therapy. Since one size doesn’t fit all, many of the country’s leading cancer centers address the challenges of metastatic cancer by offering this cutting-edge therapy as part of a personalized treatment plan.
Lu-177 PSMA therapy is typically administered by multidisciplinary team of healthcare experts, including:
Their collaborative approach ensures personalized treatment plans for each patient based on PSMA PET scans, overall health, prior treatment history, and specific needs of patients traveling from other countries.
If you or your loved one is seeking metastatic prostate cancer treatment through Lu-177 PSMA therapy in Germany, the Cancer Rounds team can provide complete assistance—serving as your anchor in a foreign healthcare system by guiding you through appointments, simplifying decisions, and ensuring a smooth treatment journey.
Lu‑177 PSMA is a targeted radioligand therapy, considered among the best treatments for metastatic castration-resistant prostate cancer (mCRPC). It is a remarkable connection of nuclear science and precision oncology. It harnesses the power of a radioactive isotope, Lutetium‑177, and couples it with a small molecule (the ligand, such as PSMA-617) designed to seek out and attach to Prostate-Specific Membrane Antigen (PSMA)—a
Once this radioligand is injected into the bloodstream, it begins its precise journey. Like a guided missile, it homes in only on the cells expressing PSMA, binding tightly to them. What makes this therapy so revolutionary is what happens next: Lutetium‑177 emits beta radiation right at the cancer cell, causing internal damage that leads to cell death—minimising damage to healthy tissues. This means fewer systemic side effects and a therapy tailored to attack where it’s needed most.
This targeted mechanism has made Lu‑177 PSMA Therapy for Hormone-Resistant Prostate Cancer in Germany one of the most promising alternatives for those with limited treatment options. In fact, it’s increasingly seen as a vital alternative for patients who’ve exhausted chemotherapy or androgen deprivation therapy.
Lu‑177 PSMA therapy is most commonly used for:
This makes Lu‑177 PSMA Therapy role in early prostate cancer cases in Germany a promising area of research and clinical trials.
Before receiving Lu‑177 PSMA therapy, patients undergo a special imaging test called a PSMA PET scan (usually with Gallium‑68 or F‑18 tracers). This scan not only confirms the presence of prostate cancer, but more importantly, it shows whether the cancer cells are expressing PSMA strongly enough to be targeted.
If the scan lights up—meaning the tumors are PSMA-positive—the patient is considered a suitable candidate for this therapy. Additional tests like blood counts, kidney function, and liver function help determine the patient’s readiness and safety profile for the treatment.
For many men around the world, the diagnosis of metastatic or hormone-resistant prostate cancer is a turning point—often filled with fear, uncertainty, and questions. What if chemo doesn’t work anymore? What if hormone therapy has failed?
That’s where Lu‑177 PSMA Therapy for Hormone-Resistant Prostate Cancer in Germany steps in—as a scientifically advanced and emotionally reassuring path forward. It offers not just another treatment, but hope grounded in data, compassion, and expertise.
This makes Germany not just a leader in innovation but also one of the safest and most reliable destinations for Lu‑177 PSMA therapy under global treatment protocols.
Germany was one of the first countries to develop and offer Lu‑177 PSMA therapy, even before FDA/EMA approval, under compassionate-use frameworks. Today, it stands as a hub for international cancer patients, offering:
Hospitals in cities like Berlin, Munich, Heidelberg, Marburg, and Cologne are well-equipped with English-speaking teams and coordinated cancer boards. Cancer Rounds provides complete end-to-end assistance for international patients seeking Lu-177 PSMA therapy for prostate cancer treatment in Germany.
Doctors qualified to administer Lu‑177 PSMA therapy must possess a unique blend of clinical, technical, and interdisciplinary expertise. These specialists are typically nuclear medicine physicians or radiation oncologists with advanced training in radioligand therapies and prostate cancer management. Key qualities include:
Top-tier doctors also ensure patient education, empathy, and transparency throughout the treatment journey. Their goal is not only to target resistant cancer cells but also to maximize quality of life and long-term outcomes.
| Hospital Name | Specialty |
|---|---|
| Helios Hospital Berlin-Buch | One of Europe’s largest nuclear medicine and oncology centers |
| University Hospital Heidelberg – National Center for Tumor Diseases (NCT) | Birthplace of PSMA therapy; pioneers in Lu‑177 development |
| University Hospital Rechts der Isar – Technical University of Munich (TUM) | Advanced nuclear medicine and personalized oncology |
| University Hospital Marburg (UKGM) | High-volume center for Lu‑177 PSMA therapy and trials |
The top doctors in Germany for Lu-177 PSMA therapy are as follows:
| Name | Specialization | Experience | Publications | Notable Expertise |
| Prof. Dr. med. Winfried Brenner | Nuclear Medicine | 32 years | 582 | Advanced radioligand therapy and PSMA-targeted theranostics |
| Prof. Dr. med. Wolfgang Weber | Nuclear Medicine, Molecular & Radionuclide Therapy | 30 years | 2,474 | Global leader in radionuclide therapy and personalized oncology |
| Prof. Dr. med. Hans-Jürgen Biersack | Nuclear Medicine | 53 years | 548 | Pioneer in theranostics and targeted radiopharmaceuticals |
| Prof. Dr. med. Frank Grunwald | Nuclear Medicine | 41 years | 524 | Expert in clinical nuclear oncology and patient-tailored therapy |
| Prof. Dr. med. Stefan Dresel | Nuclear Medicine, Radiology, Radiation Therapy, Theranostics | 34 years | 149 | Known for combining imaging and therapy in prostate cancer care |
| Prof. Dr. med. Michael Schäfers | Nuclear Medicine | 31 years | 399 | Specialist in hybrid imaging and PSMA-labeled tracers |
| Prof. Dr. med. Samer Ezziddin | Nuclear Medicine | 28 years | 252 | Authority in Lu‑177 PSMA therapy with extensive clinical trials |
| Prof. Dr. med. Uwe Haberkorn | Nuclear Medicine | 37 years | 561 | Renowned for translational research and PSMA PET-based therapies |
| Prof. Dr. med. Ambros J. Beer | Nuclear Medicine | 26 years | 410 | Focused on precision oncology and radiopharmaceutical innovation |
The cost of Lu‑177 PSMA Therapy in Germany typically ranges between €9,000 to €22,500 per cycle, depending on the medical center’s infrastructure, diagnostic protocols, and support services. A complete course of treatment—usually consisting of 3 to 4 therapy cycles—may cost between €28,000 and €60,000. This estimate generally includes essential diagnostics such as PSMA PET-CT scans, laboratory tests, inpatient hospital care, medical supervision, and post-therapy follow-ups. Many hospitals also offer bundled service packages that include interpreter assistance, local accommodation, and logistical support for international patients.
Patients can often bundle accommodation, interpreter, and transportation into complete care packages.
Cancer Rounds has dedicated case managers to provide you complete financial guidance for Lu-177 PSMA treatment in Germany. The team also provides assistance for visa and travel process, accommodation, prior virtual consultation, and in-person consultation and treatment in Germany.
Lu‑177 PSMA Therapy in Germany is primarily recommended for:
It is now also being explored for early-stage prostate cancer in high-risk patients, as shown in clinical trials assessing Lu‑177 PSMA Therapy role in early prostate cancer cases in Germany.
| Feature | Lu‑177 PSMA Therapy | Chemotherapy |
| Mechanism | Targeted radioligand therapy | Systemic cytotoxic agents |
| Side Effects | Dry mouth, fatigue, mild nausea | Hair loss, infections, fatigue |
| Tolerance | High | Moderate to poor |
| Response Rate | 45–80% | ~30–40% |
| Hospital Stay (Germany) | 3–4 days | Outpatient or admission-based |
| International Accessibility | Yes – streamlined in Germany | Varies by country |
Conclusion: For many patients, Lu‑177 offers a more precise, better-tolerated, and longer-lasting response than traditional chemotherapy.
These results make it an excellent option for patients who have exhausted traditional lines of care.
For international patients seeking the most advanced, precision-targeted treatment for metastatic castration-resistant prostate cancer (mCRPC) abroad, Lu-177 PSMA Therapy in Germany represents a revolutionary option. Germany’s leadership in nuclear medicine, radioligand therapy, and advanced prostate cancer care attracts individuals from the UK, US, Canada, Ireland, Saudi Arabia, Holland, the broader Middle East, and worldwide. If you’re an international patient navigating highly specialized medical landscapes, Cancer Rounds serves as your dedicated radiopharmaceutical therapy facilitator, prostate cancer expert, and international patient coordinator, simplifying access to Germany’s world-class Lu-177 PSMA therapy clinics and specialized services in leading nuclear medicine centers in cities like Heidelberg, Essen, Munich, and Berlin.
German medical institutions are globally recognized for their cutting-edge approach to nuclear medicine and prostate cancer, seamlessly integrating advanced diagnostics (PSMA PET/CT), specialized radiopharmaceutical production, precise therapy administration, and rigorous patient monitoring. Patients choose Germany for compelling reasons when considering Lu-177 PSMA Therapy medical tourism:
At Cancer Rounds, we deeply understand the unique complexities involved in accessing highly specialized, innovative treatments like Lu-177 PSMA Therapy – from identifying the right nuclear medicine centers and navigating stringent eligibility criteria to managing logistics for radiopharmaceutical care. We act as your essential conduit, directly connecting you with Germany’s top Lu-177 PSMA therapy clinics and leading nuclear medicine specialists in key academic hubs like Heidelberg, Essen, Munich, and Berlin. We are experts in international patient services for advanced prostate cancer therapies.
If you are from the UK exploring advanced, targeted therapies for mCRPC or require an expert assessment for Lu-177 PSMA therapy beyond what’s available through the NHS, Cancer Rounds provides direct pathways to German innovation. We facilitate prompt consultations and access to leading nuclear medicine departments, ensuring you receive comprehensive medical review from esteemed overseas specialists. This is for UK prostate cancer patients seeking treatment abroad.
Patients from the US looking for pioneering European radioligand therapy approaches, access to established Lu-177 PSMA protocols, or a second opinion from German nuclear medicine experts can leverage Cancer Rounds’ services. We offer expedited appointments and connections to leading specialists in cities like Essen and Munich, simplifying your journey to obtain advanced, personalized prostate cancer care in Germany. This is for US prostate cancer patients considering international treatment.
We recognize the unique considerations for patients from the Middle East and Saudi Arabia when pursuing cutting-edge Lu-177 PSMA therapy in Europe. Cancer Rounds meticulously streamlines your journey, arranging swift access to leading German nuclear medicine specialists in cities such as Heidelberg and Berlin, facilitating expert consultations for therapy suitability, and linking you with this precise radioligand treatment. We are your dedicated ally in securing high-quality innovative prostate cancer care in Germany without the typical logistical complexities.
Whether you are from Canada facing specific access challenges for Lu-177 PSMA therapy, or from Ireland, Holland, and other international locations seeking world-class radioligand treatment for prostate cancer, Cancer Rounds ensures a seamless and efficient process. We simplify access to specialized Lu-177 PSMA programs and personalized treatment planning in Germany’s leading nuclear medicine centers, empowering you to focus entirely on your health and potential recovery.
Cancer Rounds offers meticulous, end-to-end support tailored for patients accessing highly specialized treatments like Lu-177 PSMA Therapy. Our services encompass all logistical intricacies, including medical record translation, visa assistance, travel arrangements, specialized accommodation, and crucial language assistance throughout your medical journey in Germany. We meticulously manage these details so you can concentrate solely on your health and treatment, making international medical travel for radioligand therapy stress-free. Our extensive network guarantees you receive a bespoke treatment strategy, leveraging Germany’s advanced medical capabilities, precisely tailored to your individual needs as an international prostate cancer patient.
Do not let geographical distance or administrative complexities impede your access to pioneering Lu-177 PSMA Therapy in Germany. Let Cancer Rounds be your trusted guide to receiving timely, comprehensive, and advanced prostate cancer care in Germany’s celebrated nuclear medicine centers. Contact us for Germany cancer treatment cost information and to understand more about how to get innovative treatment in Germany for cancer.
Lu‑177 PSMA therapy is a targeted radionuclide treatment for advanced prostate cancer. It uses a radioactive isotope called Lutetium-177 attached to a molecule that binds specifically to PSMA (Prostate-Specific Membrane Antigen) found on cancer cells, delivering focused radiation to destroy them while sparing healthy tissue.
Lu‑177 PSMA therapy treatment is typically offered to patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed despite hormone therapy or chemotherapy. Eligibility is confirmed via PSMA PET-CT scan to ensure PSMA expression on cancer cells.
Germany offers world-class nuclear medicine centers, state-of-the-art imaging, experienced doctors, and access to personalized radioligand therapies. Many hospitals are involved in clinical trials and offer care that meets international standards.
The average Lutetium‑177 PSMA Therapy cost per cycle ranges from €9,000 to €22,500, depending on the hospital and services. A complete course of 3–4 cycles typically costs €28,000–€60,000, inclusive of PSMA PET-CT scans, labs, hospital stay, follow-up care, and supportive services like interpretation or accommodation.
Lu‑177 PSMA is given via intravenous injection in a controlled hospital environment. The procedure takes around 30–60 minutes. Patients may stay in the clinic for a few hours or overnight to monitor for side effects.
Top hospitals in Berlin, Munich, Heidelberg, Cologne, and Marburg offer this therapy, including academic centers and certified nuclear medicine departments with experience in PSMA-targeted radionuclide therapy.
Most side effects are mild, such as fatigue, dry mouth (xerostomia), nausea, and temporary low blood counts. Severe complications are rare but are monitored by the clinical team.
Most patients receive 3 to 6 treatment cycles, spaced 6 to 8 weeks apart, depending on response and tolerance. Doctors may adjust the schedule based on PSA levels, imaging results, and clinical symptoms.
Clinical studies from leading German centers show PSA reduction in over 70% of patients. Many experience improved quality of life, pain control, and disease stabilization, especially in late-stage prostate cancer.
In Germany, private insurance may cover the therapy partially or fully. For international patients, treatment is usually self-funded, but hospitals often provide cost estimates and payment packages in advance.
Yes. A PSMA PET-CT scan is mandatory to confirm the presence of PSMA-positive cancer cells. Without PSMA uptake, the therapy would not be effective or safe.
Absolutely. Germany welcomes medical tourists for prostate cancer treatment. Most hospitals have international departments to help with visas, travel, interpreter services, and tailored treatment planning.
German hospitals offer integrated theranostics (therapy + diagnostics), highly trained nuclear medicine physicians, and access to research-based protocols, making them leaders in precision oncology.
Doctors will evaluate your case, but many supportive or chronic condition medications can continue. Hormone therapy may also be combined if clinically indicated.
Post-treatment follow-up includes regular blood tests, PSA monitoring, and imaging (like PET or MRI) every few months. Doctors also provide supportive care and guidance for managing any long-term effects.
Published By
.webp){kind=logo}
Global Patient Care, Redefined
The CancerRounds Medical Content Team specialises in creating accurate, clear and patient-focused healthcare content. Our content is written by medically trained writers, medically reviewed, and based on reputable medical sources to support informed healthcare decisions.
Get expert guidance instantly
Share a few details and our medical team gets back to you within 4 hours with the next steps.
Tell us what you are facing and our medical team will guide you to the right doctors, hospitals and treatment.
Free Review, No Commitment
Free assessment with no pressure to proceed.
Trusted by 100,000+ Patients
Across 125+ countries worldwide
500+ Top Partner Hospitals
Globally accredited medical facilities
5000+ Expert Specialists
Senior doctors across major specialties.
Making quality healthcare accessible to patients worldwide
Everything you need to know about choosing the right hospital, doctor and treatment plan.